ANSWER: B

Rationale:

Option B is correct. This patient has classic peak-dose dyskinesia (PDD): choreiform involuntary movements of the trunk and arms that emerge approximately 40 minutes after each dose — when plasma levodopa concentrations are near their peak and the patient is in the functionally on state — and resolve as the dose wears off. The preservation of functional mobility during the dyskinetic episodes is a hallmark of PDD, distinguishing it from conditions where involuntary movements coincide with motor deterioration. The mechanism involves years of pulsatile, non-physiological D1 receptor stimulation in the setting of progressive nigrostriatal degeneration, which sensitizes direct pathway medium spiny neurons through deltaFosB accumulation and downstream AMPA/NMDA receptor upregulation. The first-line pharmacological intervention for functionally limiting PDD is amantadine — the only oral agent with Level A evidence for LID reduction, demonstrating approximately 45–60% dyskinesia reduction without a commensurate worsening of motor function in controlled trials. This dissociation between dyskinesia reduction and preserved motor benefit is the key therapeutic advantage, achieved through amantadine's uncompetitive open-channel NMDA receptor antagonism reducing the permissive glutamatergic drive. Starting at 100 mg twice daily is standard.

• Option A: Option A is incorrect; the timing — movements at peak effect, resolving as dose wears off — is the defining feature of PDD, not diphasic dyskinesia. Diphasic dyskinesia produces movements at rising and falling intermediate concentrations with relative freedom at peak.
• Option C: Option C is incorrect; off-period dystonia occurs at the overnight or pre-dose nadir when plasma levodopa is lowest, not 40 minutes post-dose when the patient is functioning well.
• Option D: Option D is incorrect; dose reduction is not first-line for PDD. It attenuates motor benefit without reliably eliminating the sensitized striatal response to levodopa, and trading dyskinesia for motor disability is not the therapeutic goal when amantadine is available.
• Option E: Option E is incorrect; the described movements — choreiform and occurring at peak dose in a PD patient on levodopa — are not levodopa-induced myoclonus. Myoclonus involves brief, shock-like muscle jerks distinct from the sustained choreiform movements of PDD, and clonazepam is not first-line management for LID.

ANSWER: D

Rationale:

Option D is correct. Livedo reticularis is a well-established, highly characteristic cutaneous adverse effect of amantadine, occurring in up to 50% of patients on long-term therapy. It presents as a mottled, reddish-purple, net-like or lace-like discoloration of the skin, most commonly affecting the lower extremities. The pathophysiology is altered vasomotor tone in the superficial cutaneous venous plexus — focal venous pooling producing the characteristic reticular pattern — not inflammation, thrombosis, or neuropathy. Despite its distinctive and sometimes alarming appearance, livedo reticularis from amantadine is entirely benign: it does not progress to ulceration, ischemia, or systemic involvement. It does not require drug discontinuation. In a patient with well-controlled dyskinesias on amantadine, the clinical benefit of continuing substantially outweighs the cosmetic concern. The appropriate management is patient education and reassurance. The absence of pain, swelling, warmth, systemic symptoms, and the intact peripheral pulses all confirm the benign vasomotor nature of this finding.

• Option A: Option A is incorrect; peripheral arterial insufficiency presents with claudication, reduced or absent pulses, and reduced ankle-brachial index — none of which are present here. Amantadine does not cause alpha-adrenergic vasoconstriction of clinical significance.
• Option B: Option B is incorrect; vasculitis would present with palpable purpura, tenderness, and constitutional or organ-involvement features. The bilateral, painless, net-like pattern without systemic features is classic livedo reticularis, not vasculitis.
• Option C: Option C is incorrect; attributing the finding to pre-existing venous insufficiency unrelated to amantadine ignores the direct causal relationship between amantadine and livedo reticularis, and compression stockings are not the management for this drug-related vasomotor effect.
• Option E: Option E is incorrect; livedo reticularis is not a manifestation of small-fiber neuropathy. It is a vasomotor phenomenon, not a neurotoxic effect, and punch skin biopsy for nerve fiber density quantification is not indicated.

ANSWER: A

Rationale:

Option A is correct. Gocovri's bedtime dosing schedule is pharmacokinetically designed around the sleep-wake cycle. The sustained-release formulation produces a characteristic profile: low plasma amantadine concentrations during the first several hours after bedtime dosing, when the patient is asleep and when amantadine's neuropsychiatric adverse effects — insomnia, nocturnal confusion, vivid dreams, and hallucinations — are most disruptive to quality of life; followed by a rising concentration curve through the early morning and daytime waking hours, when levodopa-related motor activity and peak-dose dyskinesias are most clinically active. This timing relationship is the entire pharmacological rationale for the formulation's design: it allows the delivery of higher total amantadine exposures (274 mg nightly produces plasma concentrations exceeding those achievable with standard IR dosing) while concentrating the period of lowest plasma concentration during sleep, thereby reducing neuropsychiatric adverse effects that would otherwise limit dose. If the patient were to take Gocovri in the morning instead of at bedtime, this profile would be inverted — peak concentrations would occur during the overnight sleep period, causing insomnia and nocturnal confusion, while daytime concentrations during dyskinesia-active hours would be relatively low, impairing efficacy.

• Option B: Option B is incorrect; NMDA receptor antagonism by amantadine does not require overnight receptor equilibration. Amantadine's use-dependent open-channel block is concentration-dependent and acts on acutely activated channels, not through a slow overnight receptor occupancy equilibration process.
• Option C: Option C is incorrect; Gocovri's release mechanism is not dependent on nocturnal gastric acid activation, and the formulation is not subject to food-acid interactions that would reduce bioavailability with morning dosing. The sustained-release technology is embedded in the capsule matrix, not acid-activated.
• Option D: Option D is incorrect; amantadine does not have a pharmacologically active CYP3A4-produced metabolite contributing to its antidyskinetic effect. Amantadine is excreted largely unchanged in the urine with minimal hepatic metabolism.
• Option E: Option E is incorrect; amantadine is not primarily a sedative agent, and its bedtime scheduling is not based on exploiting sedation for sleep quality. Amantadine at higher doses actually impairs sleep quality rather than improving it, which is precisely why the bedtime schedule is designed to maintain low overnight concentrations.

ANSWER: C

Rationale:

Option C is correct. This patient satisfies all established criteria for advanced therapy evaluation: confirmed idiopathic Parkinson's disease with a 47% UPDRS Part III levodopa response (well above the 30–33% candidacy threshold), refractory motor complications — functionally limiting dyskinesias and inadequate on-time — despite optimized oral pharmacotherapy including both immediate-release and extended-release amantadine, intact cognition (MoCA 27/30), no psychiatric contraindications, and no medical exclusions for either LCIG or DBS. The appropriate options include LCIG via PEG-J tube — which provides near-continuous jejunal levodopa delivery that bypasses gastric emptying variability, directly addressing the pulsatile concentration profile driving sensitized striatal overactivity — and DBS with either STN or GPi as the stimulation target. For a patient with refractory, functionally limiting dyskinesias as the primary complication, GPi DBS warrants particular consideration because it provides direct antidyskinetic benefit at the level of the basal ganglia output nucleus, independent of levodopa dose reduction, meaning levodopa doses can be maintained or increased while dyskinesias are controlled. STN DBS achieves its antidyskinetic effect primarily through levodopa dose reduction. The choice between modalities should be made by a multidisciplinary team with input from the patient.

• Option A: Option A is incorrect; there is no established hierarchy mandating STN DBS before GPi DBS in all patients with refractory dyskinesias. Both are appropriate first-line DBS options depending on clinical profile, and LCIG is not reserved only for DBS-ineligible patients — it is an independent advanced therapy option.
• Option B: Option B is incorrect; subcutaneous apomorphine infusion is not a mandatory intermediate step between oral optimization and DBS or LCIG in published guidelines. There is no required sequencing that mandates apomorphine trial before device-based therapy.
• Option D: Option D is incorrect; amantadine use does not cause jejunal mucosal changes that impair LCIG absorption or increase PEG-J infection risk. This is a fabricated contraindication with no pharmacological or clinical basis.
• Option E: Option E is incorrect; LCIG is not approved only for patients who have failed DBS. Both therapies are independently approved and may be considered in parallel based on patient clinical profile and preference.

ANSWER: E

Rationale:

Option E is correct. This patient has diphasic dyskinesia, defined by its characteristic dyskinesia-improvement-dyskinesia (D-I-D) temporal pattern: involuntary movements at dose onset (beginning-of-dose, BOD) and again at dose offset (end-of-dose, EOD) with relative freedom during the peak when motor function is best. This pattern — two windows of dyskinesia per dose cycle flanking the therapeutic peak — is the defining clinical signature of diphasic dyskinesia and is the opposite of peak-dose dyskinesia, which produces a single window of dyskinesia coinciding with peak concentration. The physician's error was misidentifying diphasic dyskinesia as PDD and applying the PDD management strategy (dose reduction) to a condition for which dose reduction is specifically contraindicated. The pharmacokinetic consequence of reducing the individual dose is that the plasma levodopa concentration curve reaches a lower peak. A lower peak means the concentration must traverse the intermediate dyskinesia-triggering range — where BOD and EOD dyskinesia are generated — for a longer time on the ascending limb before either reaching a peak or failing to reach it, and for a longer time on the descending limb. The net result is more time spent at dyskinesia-triggering intermediate concentrations and less time — possibly none — at the therapeutic peak where the patient is dyskinesia-free. This explains exactly the patient's experience: worsened movements, less time free of involuntary movements, and worse overall motor function.

• Option A: Option A is incorrect; this patient does not have PDD — the two-window-per-dose-cycle pattern with freedom at peak is specifically diphasic. Further dose reduction would worsen this further.
• Option B: Option B is incorrect; off-period dystonia occurs at the overnight or pre-dose nadir when plasma levodopa is lowest — not in two windows per dose cycle, and it is not managed by increasing the dose interval.
• Option C: Option C is incorrect; dose reduction does not increase COMT activity or 3-OMD formation as a mechanism of worsening diphasic dyskinesia. The worsening is a direct pharmacokinetic consequence of a lower peak concentration prolonging time at intermediate concentrations, not a change in peripheral metabolism.
• Option D: Option D is incorrect; delayed gastric emptying producing an atypical biphasic pattern is a distinct pharmacokinetic phenomenon and would not be temporally consistent and reproducible across five daily doses as described. Domperidone for gastric motility is not the management for diphasic dyskinesia.

ANSWER: B

Rationale:

Option B is correct. The pharmacokinetic mechanism by which entacapone benefits diphasic dyskinesia follows directly from its mechanism of action on levodopa's plasma profile. Entacapone is a peripherally acting COMT inhibitor that blocks the O-methylation of levodopa to 3-O-methyldopa (3-OMD) in the peripheral circulation, reducing levodopa's plasma clearance rate and extending its plasma half-life. The result is a modified concentration-time curve per dose: the plasma levodopa curve is broader and flatter, with a modestly attenuated peak and a prolonged therapeutic tail. For diphasic dyskinesia — which is specifically triggered when concentrations are at intermediate levels on the ascending and descending limbs — this pharmacokinetic modification is directly therapeutic. A flatter, broader curve means the concentration rises more gradually to the therapeutic peak (reducing the steepness and duration of the ascending intermediate-concentration window where BOD dyskinesia occurs), remains near the therapeutic peak for longer, and descends more gradually (reducing the steepness and duration of the descending intermediate-concentration window where EOD dyskinesia occurs). The net effect is reduced total time spent at dyskinesia-triggering intermediate concentrations and more time at the therapeutic peak — consistent with the patient's improvement.

• Option A: Option A is incorrect; entacapone is a peripherally restricted COMT inhibitor and does not substantially cross the blood-brain barrier to inhibit central COMT in the striatum. Central COMT activity and striatal dopamine conversion to 3-methoxytyramine is not the mechanism of entacapone's benefit in diphasic dyskinesia.
• Option C: Option C is incorrect; entacapone does not inhibit levodopa uptake at the large neutral amino acid transporter at the blood-brain barrier. Its site of action is peripheral COMT in the circulation, not the BBB transporter.
• Option D: Option D is incorrect; entacapone does not have D2 receptor partial agonist activity. It is an enzyme inhibitor with no established direct dopamine receptor pharmacology.
• Option E: Option E is incorrect; entacapone inhibits COMT, not aromatic amino acid decarboxylase (AADC). AADC inhibition is the mechanism of carbidopa, which is already present in the regimen.

ANSWER: D

Rationale:

Option D is correct. Diphasic dyskinesia is fundamentally a pharmacokinetic problem: it is triggered by the intermediate plasma levodopa concentrations that occur on the ascending and descending limbs of each oral dose's concentration-time curve. Any intervention that eliminates these ascending and descending intermediate-concentration phases by replacing intermittent bolus oral dosing with near-continuous drug delivery directly removes the mechanism responsible for both the BOD and EOD dyskinesia components. LCIG achieves this by delivering a continuous suspension of levodopa and carbidopa directly into the proximal jejunum via PEG-J, bypassing the gastric emptying variability that contributes to oscillating oral absorption and replacing the dose-by-dose concentration peaks and troughs with a near-steady plasma levodopa profile. This continuous delivery approach is the pharmacokinetic embodiment of the continuous dopaminergic stimulation (CDS) hypothesis — the principle that pulsatile, non-physiological receptor occupancy swings, rather than cumulative dose, drive the molecular sensitization and motor complication development underlying dyskinesia. By eliminating the pulsatile profile, LCIG addresses both the immediate dyskinesia trigger (the intermediate concentrations of each dose cycle) and the ongoing sensitization driver (the receptor occupancy oscillations). The pivotal LCIG trial demonstrated approximately 4 hours of off-time reduction with parallel dyskinesia reduction, confirming dual benefit.

• Option A: Option A is incorrect; LCIG does not work by delivering a higher total daily dose to saturate receptors continuously. Continuous receptor saturation at supraphysiological concentrations would worsen rather than improve sensitization. The benefit is pharmacokinetic stabilization within the therapeutic window, not maximization.
• Option B: Option B is incorrect; LCIG does not achieve its benefit through superior peripheral AADC inhibition eliminating peripheral dopamine fluctuations. The carbidopa in LCIG performs standard peripheral AADC inhibition; the benefit is from bypassing gastric emptying variability for continuous levodopa delivery, not from carbidopa excess.
• Option C: Option C is incorrect; LCIG delivers into the proximal jejunum — not the distal jejunum — specifically because the proximal jejunum is the primary site of levodopa absorption via the large neutral amino acid transporter. Delivery to the distal jejunum would impair absorption, not enhance it.
• Option E: Option E is incorrect; LCIG does not contain an amantadine analogue. The infusion contains only levodopa and carbidopa; there is no NMDA receptor antagonist component in the approved formulation.

ANSWER: A

Rationale:

Option A is correct. This patient has the LCIG-associated peripheral neuropathy entity, driven by carbidopa's mechanism of depleting pyridoxal phosphate (PLP). Carbidopa is a hydrazine derivative that forms stable hydrazone complexes with PLP, the active cofactor form of vitamin B6. This complexation depletes available PLP, which is required as a cofactor by cystathionine beta-synthase — the transsulfuration pathway enzyme that commits homocysteine to conversion to cystathionine. Depletion of PLP impairs this step, causing homocysteine to accumulate (plasma homocysteine 46 µmol/L confirms this). Co-existing functional B12 deficiency at a serum level of 204 pg/mL — low-normal, in the range where functional tissue deficiency can exist despite borderline-normal serum levels — further impairs homocysteine remethylation via the methylcobalamin-dependent methionine synthase pathway, compounding the hyperhomocysteinemia. The combination of B6 deficiency and hyperhomocysteinemia produces the axonal sensorimotor polyneuropathy confirmed on nerve conduction studies. The correct management is to address both deficiencies with supplementation — vitamin B6 (pyridoxine) to replete PLP and restore transsulfuration, and vitamin B12 to address functional deficiency affecting the remethylation pathway — while continuing LCIG. LCIG discontinuation is not required as the initial response; the neuropathy is metabolic and nutritional in mechanism and is addressable with supplementation in most patients, preserving the motor benefit achieved.

• Option B: Option B is incorrect; the neuropathy is not caused by levodopa-derived dopamine auto-oxidation metabolites accumulating in dorsal root ganglion cells. This mechanism is not established for LCIG-associated neuropathy, and apomorphine does not bypass CNS dopamine synthesis — it is itself converted to receptor-active dopamine agonist actions by a different mechanism.
• Option C: Option C is incorrect; the neuropathy is axonal in pattern (reduced amplitudes, preserved velocities on NCS) consistent with a metabolic/nutritional axonopathy, not demyelinating as would be expected from immune-mediated foreign body response. IVIG is not indicated.
• Option D: Option D is incorrect; while B12 deficiency is a co-contributor, attributing the neuropathy entirely to proton pump inhibitor-related B12 deficiency misses the primary LCIG-specific mechanism — carbidopa-mediated B6 depletion. The statement that carbidopa does not contribute to neuropathy at approved doses is factually incorrect — the LCIG-associated neuropathy entity is specifically linked to high daily carbidopa doses delivered by continuous infusion.
• Option E: Option E is incorrect; vitamin E deficiency causing axonal neuropathy from catheter-tip jejunal mucosal trauma is a fabricated mechanism with no basis in the established clinical literature on LCIG complications.

ANSWER: C

Rationale:

Option C is correct. This patient has classic off-period dystonia — specifically early morning foot dystonia, one of the most common and recognizable presentations of this phenomenon. The pathophysiology is straightforward: her last levodopa dose is at 10 PM, and her episodes occur between 4 and 5 AM — six to seven hours after the last dose and two to three hours before the first morning dose, precisely when plasma levodopa concentrations are at their overnight nadir and dopaminergic stimulation is at its lowest. Insufficient D1 and D2 receptor occupancy in the basal ganglia motor circuit increases inhibitory GPi/SNr output to the thalamus, producing the sustained involuntary contraction and equinovarus posturing of the foot and calf characteristic of off-period dystonia. The resolution with the 7 AM levodopa dose is diagnostically confirmatory. The appropriate initial intervention is to add controlled-release (CR) carbidopa/levodopa at bedtime — the most direct pharmacological correction for the overnight dopaminergic deficit. CR tablets release levodopa gradually over 6–8 hours, extending plasma concentrations through the early morning hours and reducing the depth and duration of the pre-dawn trough that triggers the dystonic episodes. This intervention directly addresses the pathophysiology without altering the existing effective daytime regimen.

• Option A: Option A is incorrect; levodopa has a plasma half-life of approximately 90 minutes, so the 10 PM dose is essentially cleared by midnight. There is no overnight accumulation causing peak-dose effects at 4–5 AM — the problem is the opposite: excessive depletion, not accumulation.
• Option B: Option B is incorrect; delaying the first morning dose to 9 AM would extend the overnight off-period by two additional hours, substantially worsening the foot dystonia rather than treating it.
• Option D: Option D is incorrect; the temporal relationship to the overnight levodopa interval — consistent onset 6–7 hours after the last dose, resolution with levodopa — is highly specific for off-period dystonia and is not consistent with electrolyte-related leg cramps, which do not resolve promptly with dopaminergic medication.
• Option E: Option E is incorrect; REM sleep behavior disorder presents with vocalizations and complex movements during REM sleep that enact dreams, not with sustained painful equinovarus foot posturing that resolves with levodopa. The described episodes resolve with the first morning dose, not spontaneously upon awakening, distinguishing them from parasomnia.

ANSWER: E

Rationale:

Option E is correct. The pharmacological rationale for adding a long-acting dopamine agonist at bedtime for residual early morning foot dystonia is pharmacodynamic bridging of the overnight dopaminergic gap. Long-acting formulations of pramipexole (extended-release) and ropinirole (extended-release) have plasma half-lives of 8–12 hours, meaning a dose taken at bedtime produces therapeutic plasma concentrations throughout the overnight period and into the early morning hours. These agents act directly at postsynaptic D2 and D3 receptors in the striatum without requiring presynaptic conversion, providing continuous receptor stimulation independent of the levodopa concentration curve. During the hours when CR carbidopa/levodopa coverage becomes insufficient — as shown by persistent early morning dystonia in this patient — the agonist maintains sufficient dopaminergic receptor tone to prevent the basal ganglia motor circuit from shifting into the uninhibited GPi/SNr output state that produces off-period dystonia. This mechanism is genuinely distinct from and complementary to CR levodopa: the agonist provides pharmacodynamic continuity through direct receptor action while CR levodopa provides pharmacokinetic coverage through substrate delivery; together they provide more complete overnight protection than either alone.

• Option A: Option A is incorrect; dopamine agonists do not inhibit peripheral COMT and do not extend plasma levodopa concentrations through any pharmacokinetic mechanism. COMT inhibition is the mechanism of entacapone and related drugs, not dopamine agonists.
• Option B: Option B is incorrect; long-acting dopamine agonists are postsynaptic receptor agonists, not D2 autoreceptor blockers that reduce reuptake. D2 autoreceptor blockade would reduce dopamine synthesis and release — the opposite of the desired effect.
• Option C: Option C is incorrect; dopamine agonists do not inhibit MAO-B. MAO-B inhibition is the mechanism of rasagiline, selegiline, and safinamide.
• Option D: Option D is incorrect; reducing direct pathway MSN sensitivity to the onset of the 7 AM levodopa dose is not the mechanism by which dopamine agonists address overnight off-period dystonia, and this framing conflates the overnight trough problem with the onset of the next morning dose.

ANSWER: B

Rationale:

Option B is correct. This patient's daytime wearing-off — emerging 45 minutes before each of four daily doses in a patient who is otherwise well-controlled on her current individual dose — is a classic timing problem, not a dose insufficiency. The effective duration of her carbidopa/levodopa 25/100 mg dose does not cover the inter-dose interval at four-times-daily dosing, producing predictable pre-dose troughs. The first step in the wearing-off management algorithm is to shorten the dose interval — increasing from four to five or six daily doses while maintaining the current individual dose or making only modest increases — correcting the timing deficit without amplifying peak concentrations or introducing unnecessary dyskinesia risk. This patient's excellent response during the on-state confirms her current dose is therapeutically adequate; the problem is that each dose wears off before the next is due. Interval shortening directly corrects this. COMT inhibitor addition is the second step when interval adjustment alone is insufficient.

• Option A: Option A is incorrect; increasing the individual dose while maintaining the same frequency addresses peak concentration rather than interval length — it does not correct the fact that 45 minutes of off-time occurs before each scheduled dose because the interval is too long. Higher individual doses at four-times-daily spacing will still produce wearing-off 45 minutes before each dose, and higher peaks increase dyskinesia risk.
• Option C: Option C is incorrect; switching all daytime doses to CR formulation is not the established first step in wearing-off management, and the evidence for CR formulations reducing wearing-off versus optimized IR dosing is modest. Her successful bedtime CR use reflects the specific pharmacological need for overnight coverage, not a general indication that CR is superior for daytime dosing.
• Option D: Option D is incorrect; entacapone is the second-line intervention in the wearing-off algorithm, appropriate when interval adjustment alone is insufficient. Applying it as the first step before attempting interval shortening bypasses the established first-line intervention.
• Option E: Option E is incorrect; rasagiline is the third-line intervention in the wearing-off algorithm, appropriate when both interval adjustment and COMT inhibition have been added. Applying it as the first intervention is not consistent with the established management sequence.

ANSWER: D

Rationale:

Option D is correct. The most important single finding confirming DBS eligibility is the levodopa challenge result: a 44% improvement in UPDRS Part III motor score, which exceeds the established minimum threshold of 30–33% improvement required for DBS candidacy. This criterion is pharmacologically fundamental because DBS modulates the output nuclei of the basal ganglia — the STN or GPi — to reduce excessive inhibitory drive to the thalamus, thereby improving motor function through the same circuit that levodopa improves by restoring dopaminergic signaling. The mechanistic implication is that symptoms which respond to levodopa will respond to DBS, because both interventions improve the same motor circuit dysfunction through complementary mechanisms. Symptoms that do not respond to levodopa — postural instability, freezing of gait, dysarthria, autonomic dysfunction — will not respond to DBS. A patient who does not demonstrate at least 30–33% levodopa response cannot be expected to obtain meaningful motor benefit from DBS regardless of other eligibility criteria being met. The 44% response in this patient is the pharmacological guarantee of predicted DBS benefit.

• Option A: Option A is incorrect; there is no specific minimum disease duration criterion for DBS candidacy in established guidelines. Disease duration is relevant to confirming the diagnosis of idiopathic PD, but it is not stated as a minimum year threshold in current DBS selection criteria.
• Option B: Option B is incorrect; MoCA 26/30 confirms the absence of a disqualifying contraindication — cognitive impairment — but it does not confirm DBS eligibility on its own. The absence of a contraindication is a necessary but not sufficient condition for candidacy. The levodopa response is the single most important positive confirmation of predicted benefit.
• Option C: Option C is incorrect; the absence of LCIG contraindications does not confirm DBS candidacy by exclusion — both therapies may be appropriate, and the eligibility criteria for each are independent. DBS eligibility requires positive confirmation of levodopa responsiveness.
• Option E: Option E is incorrect; there is no established minimum off-state UPDRS Part III score threshold for DBS candidacy. The absolute severity of off-state disability is not the criterion — the proportional improvement with levodopa is.

ANSWER: C

Rationale:

Option C is correct. This patient has developed an NMS-like dopaminergic withdrawal syndrome from the simultaneous abrupt discontinuation of both carbidopa/levodopa and amantadine on the morning of surgery. The clinical presentation — hyperthermia, severe lead-pipe rigidity, autonomic instability (tachycardia, diaphoresis), markedly reduced consciousness, and CK elevation from rhabdomyolysis — is indistinguishable from classic neuroleptic malignant syndrome and occurs by the same pathophysiological mechanism: abrupt reduction in central dopaminergic tone causing disinhibition of thermoregulatory and motor circuits. Amantadine's contribution to the severity of this syndrome is pharmacologically important and often underappreciated: in addition to its NMDA receptor antagonism, amantadine enhances dopamine synthesis and release from presynaptic terminals and inhibits dopamine reuptake via the dopamine transporter. These dopaminergic properties contribute meaningfully to maintaining central dopaminergic tone, particularly in a patient with advanced PD and severely depleted nigrostriatal reserve. When both levodopa and amantadine are simultaneously discontinued, the combined loss of exogenous levodopa substrate and amantadine's dopaminergic augmentation produces a more abrupt and severe dopaminergic deficit than levodopa discontinuation alone. This is a preventable perioperative catastrophe: amantadine must never be abruptly discontinued in patients on chronic high-dose therapy, and if the patient cannot take oral medications postoperatively, it should be given via nasogastric tube.

• Option A: Option A is incorrect; serotonin syndrome presents with clonus, hyperreflexia, and hyperthermia but not with the severe lead-pipe rigidity of NMS. Levodopa does not substantially increase central serotonin, and the timing — onset on postoperative day 2 following medication discontinuation — points to withdrawal, not a serotonergic interaction.
• Option B: Option B is incorrect; malignant hyperthermia is triggered intraoperatively during volatile anesthetic administration, not on postoperative day 2. It is caused by RYR1 gene mutations causing uncontrolled skeletal muscle calcium release, not by amantadine-related calcium buffering impairment.
• Option D: Option D is incorrect; while amantadine has mild anticholinergic properties, anticholinergic toxidrome produces dry flushed skin, tachycardia, and confusion but not the severe lead-pipe rigidity or CK elevation of NMS. Physostigmine is not the management for this presentation.
• Option E: Option E is incorrect; septic encephalopathy does not produce severe lead-pipe rigidity or markedly elevated CK from rhabdomyolysis. The temporal relationship to medication discontinuation on the day of surgery with onset 48 hours later is specifically consistent with amantadine withdrawal kinetics given the drug's 10–18 hour half-life and its prolongation in an elderly patient.

ANSWER: A

Rationale:

Option A is correct. The management of NMS-like dopaminergic withdrawal syndrome is fundamentally different from idiopathic NMS caused by dopamine receptor blockade: whereas idiopathic NMS requires stopping the offending dopamine antagonist, withdrawal NMS requires the opposite — rapid restoration of the withdrawn dopaminergic medications. The cornerstone of treatment is immediate re-establishment of dopaminergic tone. Carbidopa/levodopa should be crushed and administered via nasogastric tube without delay — even small levodopa doses can begin to reverse the dopaminergic deficit responsible for the syndrome. Amantadine should similarly be restarted via nasogastric tube. Critically, the care team must identify and immediately stop any dopamine antagonist antiemetics that may have been administered perioperatively — metoclopramide, prochlorperazine, or haloperidol — as these would compound the central dopamine receptor blockade and worsen the syndrome. Concurrent supportive measures are essential: active cooling for hyperthermia, aggressive IV fluid hydration to prevent acute kidney injury from rhabdomyolysis (CK 4,800 U/L), continuous cardiac monitoring for arrhythmia, and intensive care unit-level monitoring. Dantrolene — a ryanodine receptor antagonist that reduces skeletal muscle calcium release and rigidity — may be considered as an adjunct if rigidity is severe and life-threatening and dopaminergic restoration is delayed.

• Option B: Option B is incorrect; withholding levodopa and amantadine for 48 hours while treating with dantrolene alone misses the fundamental treatment — dopaminergic restoration. Dantrolene addresses the symptom (rigidity) but not the cause (dopamine deficiency). Rebound dyskinesias are not a reason to delay re-establishing the medications that are keeping the patient alive.
• Option C: Option C is incorrect; bromocriptine is an older dopamine agonist that has been used as an adjunct in NMS, but it is not the primary treatment and should not replace levodopa and amantadine. The claim that levodopa and amantadine should not be restarted due to adverse interaction with bromocriptine is pharmacologically baseless.
• Option D: Option D is incorrect; lorazepam may provide modest ancillary benefit for agitation and autonomic instability but does not address the underlying dopamine deficiency and is not primary treatment. Permanently discontinuing amantadine after this episode would leave the patient without dyskinesia management and is not indicated — the syndrome was caused by abrupt withdrawal, not by the drug itself.
• Option E: Option E is incorrect; haloperidol is a D2 receptor antagonist and would profoundly worsen an NMS-like withdrawal syndrome by further blocking the dopamine receptors that are already understimulated. This is the exact opposite of appropriate management.

ANSWER: E

Rationale:

Option E is correct. Amantadine's renal dosing adjustment is based directly on creatinine clearance because the drug is excreted largely unchanged in the urine with minimal hepatic metabolism. For creatinine clearance in the range of 30–50 mL/min, the established dosing guidance specifies reduction to 100 mg once daily. This patient's CrCl of 35 mL/min falls squarely in this range. At 100 mg once daily, the reduced elimination rate from CrCl 35 mL/min is partially offset by the halved dose, maintaining plasma concentrations within a safer range than the previous twice-daily regimen while still providing antidyskinetic benefit. Careful monitoring for neuropsychiatric adverse effects — the concentration-dependent toxicity most likely to manifest with accumulation — is essential, as is reassessment of his renal function. His CrCl may improve as the acute kidney injury from rhabdomyolysis resolves; if it returns to his pre-operative baseline of 58 mL/min, the dosing can be reassessed. The dose should not be returned to 200 mg twice daily until renal function is confirmed stable at a level supporting that dosing.

• Option A: Option A is incorrect; the dose adjustment threshold for amantadine is CrCl below 50 mL/min, not below 15 mL/min. At CrCl 35 mL/min, dose reduction is clearly required. Restarting 200 mg twice daily would cause rapid accumulation with high risk of recurrent neuropsychiatric toxicity.
• Option B: Option B is incorrect; acute kidney injury is not a lifetime contraindication to amantadine. The drug can be used with appropriate dose adjustment as renal function recovers. The previous withdrawal syndrome was caused by abrupt discontinuation, not by amantadine itself; careful reintroduction at an appropriate dose is appropriate.
• Option C: Option C is incorrect; the amantadine renal dose adjustment thresholds apply to all patients based on creatinine clearance, not only those over age 80. There is no age restriction on when renal dosing adjustments are required.
• Option D: Option D is incorrect; increasing the total daily dose to three times daily is the opposite of the correct approach for CrCl 35 mL/min. Impaired renal tubular secretion in this setting prolongs the half-life and requires dose reduction, not dose increase.

ANSWER: B

Rationale:

Option B is correct. Both amantadine and ondansetron carry recognized QTc prolongation risks through effects on cardiac ion channels — specifically the hERG (human ether-à-go-go related gene) potassium channel that mediates the cardiac repolarization current IKr. Blockade of this channel delays ventricular repolarization and prolongs the QTc interval. The additive pharmacodynamic interaction between two QTc-prolonging agents in a patient whose baseline QTc is already 458 ms — at the upper limit of normal — is clinically significant because the combined effect of both drugs may push the QTc toward or above 500 ms, a threshold associated with substantially increased risk of torsades de pointes, a potentially fatal ventricular arrhythmia. The approach should be to assess the combined effect with a repeat ECG, minimize ondansetron exposure by switching from scheduled twice-daily dosing to as-needed dosing at the lowest effective dose, and evaluate alternatives. The difficulty here is that metoclopramide — a common antiemetic alternative — is a dopamine D2 antagonist that could worsen parkinsonism or precipitate NMS in this already-vulnerable patient, making it inappropriate. Safer antiemetic alternatives include domperidone (limited CNS penetrance, less risk of parkinsonism worsening) or low-dose lorazepam for nausea.

• Option A: Option A is incorrect; amantadine's QTc effects are not dose-thresholded at 300 mg/day with zero effect below that level. QTc prolongation is a pharmacological property across the dose range, and the interaction risk at a baseline QTc of 458 ms is clinically relevant regardless of dose.
• Option C: Option C is incorrect; amantadine is not metabolized by CYP2D6 — it is excreted largely unchanged in the urine with minimal hepatic metabolism. There is no CYP2D6-based pharmacokinetic interaction between ondansetron and amantadine.
• Option D: Option D is incorrect; pharmacodynamic QTc interactions do not require identical mechanisms to be additive — they require convergent effects on the same functional outcome, which here is QTc prolongation via IKr channel blockade. The fact that amantadine and ondansetron act on hERG channels through potentially different molecular interactions does not prevent the additive QTc effect.
• Option E: Option E is incorrect; a QTc of 458 ms is not above an absolute 440 ms threshold for all QTc-prolonging medications. Clinical guidelines recommend monitoring and risk assessment rather than absolute contraindication at this level, and the threshold for absolute contraindication in most guidelines is 500 ms or greater.

ANSWER: D

Rationale:

Option D is correct. The levodopa challenge result — 39% UPDRS Part III improvement — is the finding that most directly confirms DBS eligibility by providing the mechanistic basis for predicting benefit. DBS modulates the output nuclei of the basal ganglia (STN or GPi) to reduce excessive inhibitory drive from these nuclei to the thalamus and cortex, improving the motor circuit function that is disrupted in Parkinson's disease. Crucially, DBS improves motor function through the same circuit that levodopa improves by restoring dopaminergic signaling: both interventions ultimately increase thalamocortical activation by reducing basal ganglia inhibitory output, through complementary mechanisms at different points in the circuit. This mechanistic parallel means that levodopa responsiveness — measured formally as the proportional improvement in UPDRS Part III motor score with levodopa challenge — is the best predictor of DBS motor benefit. Symptoms that improve with levodopa will improve with DBS; symptoms that do not respond to levodopa (postural instability, freezing, dysarthria, autonomic dysfunction) will not respond to DBS regardless of stimulation parameters. The 30–33% threshold has been validated across the major DBS trials as the minimum levodopa response predictive of clinically meaningful DBS benefit. This patient's 39% response exceeds the threshold.

• Option A: Option A is incorrect; confirming idiopathic PD is a necessary prerequisite for DBS candidacy, but it is not the finding that predicts DBS benefit — it eliminates a disqualifying condition rather than confirming the mechanistic basis for improvement.
• Option B: Option B is incorrect; MoCA 27/30 confirms the absence of a contraindication — an important element — but does not directly predict motor benefit from DBS. It is a necessary condition, not a sufficient one.
• Option C: Option C is incorrect; depression in remission does not contraindicate DBS and represents appropriate pre-operative optimization, but it does not predict DBS motor benefit.
• Option E: Option E is incorrect; refractory motor complications establish the clinical indication for advanced therapy but do not mechanistically predict DBS benefit. A patient with refractory complications who does not respond adequately to levodopa would not benefit from DBS despite meeting the refractory threshold.

ANSWER: C

Rationale:

Option C is correct. This patient's clinical profile specifically favors GPi as the DBS target for two converging reasons. First, his history of mild depression and documented mildly reduced processing speed represent pre-existing neuropsychiatric vulnerabilities that increase his risk from the mood and cognitive adverse effects associated with STN stimulation. The VA/NINDS cooperative study found that GPi DBS patients had better scores on the Mattis Dementia Rating Scale and better depressive symptom measures at 24 months compared with STN DBS patients — a difference attributed to stimulation effects on limbic STN subdivisions and cognitive circuits that are less involved in GPi stimulation. For a patient with any pre-existing mood or cognitive vulnerability, GPi's more favorable neuropsychiatric profile is clinically determinative. Second, his primary motor complication is refractory peak-dose dyskinesia, and GPi DBS provides direct antidyskinetic benefit through modulation of the GPi — the final output nucleus of the basal ganglia — that is independent of levodopa dose reduction. This means his levodopa can be maintained or even increased to support motor function and mood without being limited by dyskinesia, which is pharmacologically important given that dopaminergic tone also contributes to mood regulation via mesolimbic pathways. STN DBS achieves its antidyskinetic effect primarily through the levodopa dose reduction it permits, which in this patient would withdraw dopaminergic support from mood circuits.

• Option A: Option A is incorrect; the VA/NINDS cooperative study did not find that STN DBS eliminated neuropsychiatric risk in patients with pharmacologically controlled depression — it found that GPi DBS patients had better mood and cognitive outcomes regardless of pre-operative psychiatric status. Controlled depression does not neutralize STN stimulation's neuropsychiatric risk.
• Option B: Option B is incorrect; the VA/NINDS cooperative study did not find STN DBS to be superior in overall UPDRS motor scores at any time point — it found equivalent motor outcomes between the two targets, making neuropsychiatric profile differences the determinative clinical factor.
• Option D: Option D is incorrect; DBS target selection is not determined by FDA indication specificity for dyskinesia versus wearing-off — both STN and GPi DBS are approved for advanced PD motor complications broadly, and clinical factors guide target selection.
• Option E: Option E is incorrect; the VA/NINDS study did find significant differences favoring GPi in cognitive and mood outcomes — it explicitly did not demonstrate equivalence across all outcomes. Ignoring these differences to make the decision "solely surgical preference" is not appropriate clinical practice.

ANSWER: A

Rationale:

Option A is correct. This patient's post-operative depression reflects the convergence of two distinct pharmacological mechanisms that the clinical team had specifically sought to avoid by recommending GPi DBS. First, bilateral STN DBS carries a recognized risk of mood and neuropsychiatric adverse effects. The STN has motor, associative, and limbic functional subdivisions; stimulation of the limbic STN — or current spread to adjacent limbic circuitry including the substantia nigra pars reticulata, medial forebrain bundle, or ventral striatum — produces direct mood-modulating effects that can manifest as depression, anxiety, or dysphoria. The VA/NINDS cooperative study documented higher rates of depressive symptoms and worse Mattis DRS scores in STN compared with GPi DBS patients at 24 months, reflecting these neuropsychiatric effects. Second, the 50% levodopa dose reduction standard after STN DBS withdraws substantial dopaminergic support from the mesolimbic and mesocortical pathways — the ventral tegmental area projections to the limbic system and prefrontal cortex — that regulate mood, motivation, hedonic responsiveness, and anhedonia resistance. For a patient with pre-existing mild depression, even in remission, this combined withdrawal can unmask or precipitate a clinically significant depressive episode. The passive suicidal ideation without prior history in this patient requires urgent psychiatric evaluation and represents the clinical hazard that the team sought to minimize by recommending GPi instead. The management requires addressing both mechanisms: urgent psychiatry consultation, consideration of partial levodopa dose restoration, and DBS programming review by the team.

• Option B: Option B is incorrect; this presentation — passive suicidal ideation, anhedonia, functional impairment — is not a grief response. It is a neuropsychiatric syndrome with pharmacological underpinnings requiring active management, not watchful waiting with psychotherapy.
• Option C: Option C is incorrect; STN DBS does not destroy dopaminergic neurons through current spread. The electrode targets the STN, which is distinct from the SNc, and current spread sufficient to cause neuronal destruction is not a recognized mechanism of DBS.
• Option D: Option D is incorrect; sertraline withdrawal is not the explanation here. Sertraline should be continued perioperatively in patients with a history of depression, and abruptly stopping it would only add to the patient's risk rather than account for this presentation. The correct explanation is the dual pharmacological mechanism of limbic STN stimulation and levodopa dose reduction. The option's claim that dopaminergic pathways do not contribute to mood at therapeutic levodopa doses is also false — mesolimbic and mesocortical dopaminergic signaling contributes substantially to mood regulation in PD.
• Option E: Option E is incorrect; STN DBS does carry an independent neuropsychiatric risk beyond levodopa reduction. The VA/NINDS cooperative study did find differences in mood and cognitive outcomes favoring GPi DBS, and attributing the entire depression to levodopa reduction alone misses the stimulation-related contribution.

ANSWER: E

Rationale:

Option E is correct. The STN has a well-characterized functional topography: the dorsolateral portion processes sensorimotor information and is the target for motor benefit in PD; the ventromedial portion processes limbic and associative information. Current electrode contacts at the ventromedial STN border — particularly in a patient who has developed depression after STN DBS — represent a clinically actionable situation: the stimulation may be inadvertently activating the limbic STN subdivision or spreading to adjacent limbic structures, including the substantia nigra pars reticulata and medial forebrain bundle fibers, contributing to the mood adverse effects. Switching stimulation to a more dorsolateral contact — targeting the sensorimotor STN subdivision — is a standard first-line programming adjustment when post-DBS neuropsychiatric adverse effects are identified. This move preserves motor benefit through continued sensorimotor STN modulation while reducing activation of limbic-associated tissue. In practice, the programming team adjusts contact selection, amplitude, pulse width, and frequency to optimize the therapeutic window between motor benefit and neuropsychiatric adverse effects. This programming-based approach is a key clinical tool in managing post-STN DBS psychiatric complications without requiring device revision.

• Option A: Option A is incorrect; moving dorsolaterally does not target corticospinal tract fibers for supplementary motor cortex activation. Inadvertent corticospinal tract stimulation at dorsolateral contacts is actually an adverse effect to avoid (it produces tonic muscle contractions), not a therapeutic goal.
• Option B: Option B is incorrect; contact selection does not meaningfully affect battery drain or infection risk. Battery life is primarily determined by the total electrical charge delivered (amplitude × pulse width × frequency), not by dorsolateral versus ventromedial contact position.
• Option C: Option C is incorrect; the SNc is not dorsolateral to the STN. The STN is located dorsal and lateral to the SNc; moving the stimulation contact dorsolaterally moves it away from the SNc, not toward it. Additionally, DBS stimulation does not accelerate dopaminergic neuronal apoptosis through calcium influx — this mechanism is fabricated.
• Option D: Option D is incorrect; the corticospinal tract is lateral and slightly posterior to the STN, and ventromedial contacts are actually further from the corticospinal tract than dorsolateral ones. Motor fluctuations in PD are caused by dopaminergic pharmacokinetics, not by corticospinal tract overstimulation.

ANSWER: B

Rationale:

Option B is correct. Significant cognitive impairment is one of the core contraindications to DBS and is among the most important screening criteria in candidate evaluation. DBS does not benefit cognition — it modulates motor circuits but has no established mechanism for cognitive improvement — and both the surgery itself and the ongoing stimulation carry neuropsychiatric risks that are substantially amplified in patients with pre-existing cognitive impairment. Patients with dementia are at higher risk for postoperative delirium, stimulation-induced cognitive worsening, inability to communicate adverse effects to the programming team, and functional deterioration that offsets any motor benefit. A MoCA score of 19/30 is in the mild-to-moderate dementia range, well below the cognitive threshold that DBS candidacy requires. This is not a relative contraindication to be weighed against motor benefit — it is a disqualifying criterion because the risk-benefit calculus is unfavorable. The patient's 43% levodopa response confirms that other advanced therapies with more appropriate risk profiles should be pursued.

• Option A: Option A is incorrect; there is no established 15-year disease duration maximum for DBS candidacy. Duration is used to confirm idiopathic PD diagnosis, not as an age-out threshold for benefit.
• Option C: Option C is incorrect; active IBD is a contraindication to LCIG via PEG-J tube implantation, not to DBS. While immunosuppressive medications in IBD patients may modestly increase surgical infection risk, active IBD is not a recognized contraindication to DBS. The primary contraindication to DBS in this patient is her cognitive impairment.
• Option D: Option D is incorrect; there is no established upper threshold for levodopa response above which DBS is appropriate and below which it is not, other than the minimum 30–33% threshold. A 43% response is well above the minimum and does not disqualify the patient on this basis.
• Option E: Option E is incorrect; caregiver support is not a contraindication to DBS — it is a facilitating factor. DBS programming adjustments can be managed with caregiver assistance, and caregiver involvement is actually a positive element in advanced therapy decision-making.

ANSWER: D

Rationale:

Option D is correct. LCIG via PEG-J tube delivers a continuous suspension of levodopa and carbidopa directly into the proximal jejunum through a jejunal extension tube placed via percutaneous endoscopic gastrostomy. Active Crohn's disease involving the proximal jejunum — the exact anatomical location of the infusion tip — is a specific clinical contraindication for multiple reasons. First, the PEG-J placement procedure requires upper gastrointestinal endoscopy through inflamed bowel, carrying risk of worsening mucosal injury during scope passage. Second, continuous delivery of the carbidopa/levodopa gel into actively inflamed jejunal mucosa may exacerbate the inflammatory process and impair the consistent absorption that the procedure requires. Third, active IBD at the tube site substantially increases the risk of PEG site infection, peritonitis from tube complications, and tube displacement from friable inflamed tissue. Fourth, absorption of levodopa may be erratic through inflamed mucosa, undermining the pharmacokinetic rationale for the procedure. LCIG could potentially be reconsidered if her Crohn's disease achieves deep remission — clinically, biochemically, and endoscopically — with normal-appearing proximal jejunal mucosa confirming that the inflammatory process is controlled at the planned infusion site. Her cognitive impairment, while not a formal LCIG contraindication in the same way it is for DBS, is a practical challenge that caregiver support (her daughter) can substantially address.

• Option A: Option A is incorrect; LCIG does not have a formal MoCA score contraindication threshold analogous to DBS. Unlike DBS, where the cognitively impaired patient cannot independently communicate stimulation-related symptoms, LCIG device management can be substantially assisted or fully managed by a committed caregiver, making cognitive impairment a practical challenge rather than an absolute contraindication.
• Option B: Option B is incorrect; LCIG is not restricted to patients with levodopa responses above 50%. The same 30–33% UPDRS levodopa response threshold that applies to DBS candidacy applies to the general assessment of levodopa-responsiveness, and there is no higher threshold specific to LCIG.
• Option C: Option C is incorrect; chronic amantadine use does not cause jejunal mucosal metaplasia or impair LCIG absorption. This is a fabricated contraindication.
• Option E: Option E is incorrect; LCIG guidelines do not prohibit caregiver operation of the pump. Caregiver operation is specifically a supportive factor for patients with cognitive impairment considering LCIG, not a contraindication.

ANSWER: C

Rationale:

Option C is correct. Apomorphine is a potent full dopamine agonist — not a dopamine precursor — that directly stimulates postsynaptic D1 and D2 receptors in the striatum without requiring presynaptic conversion. It does not need surviving nigrostriatal terminals to exert its effect, which is pharmacologically important in advanced PD where terminal density is severely depleted. When delivered as a continuous subcutaneous infusion via a programmable pump, it provides near-continuous dopaminergic receptor stimulation — the pharmacological goal of the continuous dopaminergic stimulation (CDS) hypothesis. By maintaining stable receptor occupancy throughout the waking period rather than producing the peaks and troughs of oral dosing, subcutaneous apomorphine infusion addresses both the wearing-off caused by inadequate stimulation during troughs and the pulsatile sensitization driver underlying dyskinesia. Critically for this patient, the subcutaneous route bypasses the gastrointestinal tract entirely — the infusion does not involve the jejunum, duodenum, stomach, or any part of the bowel affected by her Crohn's disease — making it pharmacokinetically and procedurally independent of her IBD. It also eliminates the gastric emptying variability that contributes to erratic oral levodopa absorption in advanced PD. The practical requirements for subcutaneous apomorphine — injection site rotation to prevent nodules, nausea prophylaxis with domperidone during initiation, and pump management — can all be managed by her engaged daughter caregiver.

• Option A: Option A is incorrect; apomorphine is a dopamine receptor agonist, not an AADC inhibitor. It does not block peripheral decarboxylation and contains no levodopa — it acts directly at postsynaptic dopamine receptors without requiring any conversion.
• Option B: Option B is incorrect; apomorphine is not a dopamine reuptake inhibitor. DAT inhibition is the mechanism of cocaine and some stimulant drugs. Apomorphine's mechanism is direct dopamine receptor agonism at D1 and D2 receptors.
• Option D: Option D is incorrect; apomorphine does not stimulate dopamine synthesis through tyrosine hydroxylase activation. It bypasses endogenous synthesis entirely by acting directly at postsynaptic receptors. Additionally, subcutaneous apomorphine does not undergo CYP3A4 first-pass metabolism — apomorphine is not substantially metabolized by CYP3A4.
• Option E: Option E is incorrect; apomorphine is not a levodopa precursor and is not converted to dopamine in subcutaneous adipose tissue. It is itself the pharmacologically active compound that acts directly at dopamine receptors.

ANSWER: A

Rationale:

Option A is correct. Subcutaneous injection site nodules and skin changes — including fibrosis, discoloration, and induration — are one of the most common and clinically significant adverse effects of long-term subcutaneous apomorphine infusion. The mechanism is a local tissue reaction to the continuous presence of the infusion catheter and the drug at the same anatomical site: repeated or prolonged mechanical trauma from the catheter combined with the local chemical effect of apomorphine produces adipocyte hypertrophy, fibrous tissue deposition, and inflammatory changes that manifest as subcutaneous nodules. In advanced cases, skin necrosis can occur. This is not an idiosyncratic or allergic reaction — it is a predictable tissue response to prolonged localized drug delivery that occurs in the majority of long-term users. The primary prevention and management strategy is strict, systematic site rotation: the catheter insertion site must be changed every 24–48 hours to a new anatomical location that has not recently been used, following a documented rotation map that distributes infusion sites across the abdomen and thighs. The current 3-week dwell time at a single site in this patient is far beyond the recommended interval and is directly responsible for the nodule severity described. Previously affected sites should be rested until resolved before reuse. Ultrasound can identify areas of undamaged subcutaneous tissue for site selection when extensive nodulosis has occurred.

• Option B: Option B is incorrect; the nodules are not a systemic alkaloid-mediated immune reaction, and subcutaneous corticosteroid injection is not standard management. Switching to oral pramipexole would sacrifice the continuous delivery benefit that is the therapeutic rationale for the subcutaneous route in this patient.
• Option C: Option C is incorrect; apomorphine-related subcutaneous nodules are not melanoma precursors. While patients with PD have a slightly increased risk of melanoma (related to shared melanocytic regulatory biology), this is disease-related and not caused by apomorphine injection site nodules specifically.
• Option D: Option D is incorrect; site rotation is the primary management strategy for injection site nodules and is definitively indicated. The statement that rotation increases cumulative nodule risk by exposing more sites is pharmacologically backwards — prolonged dwell at a single site causes nodulosis, and rotation is the prevention.
• Option E: Option E is incorrect; intravenous apomorphine via central venous catheter is not an established clinical practice. The subcutaneous route is the standard delivery route for continuous apomorphine infusion; the appropriate response to site nodulosis is site rotation, not conversion to central venous delivery.